drugset / Trial / NCT03907033

Liposomal Bupivacaine in Vaginal Hysterectomy

NCT03907033 ↗

Phase 4 Terminated 28 enrolled Mayo Clinic Pacira Pharmaceuticals, Inc · collab
RandomizedParallel-groupTriple-blindPrevention

Summary

The aim of this study is to compare the effects of preemptive analgesia using liposomal bupivacaine mixed with bupivacaine HCl, versus bupivacaine HCl alone for uterosacral ligament injection in patients undergoing vaginal hysterectomy. We hypothesize that the group receiving a combination of liposomal bupivacaine and bupivacaine HCl will report superior postoperative pain management. Enhancement in pain control should confer a decrease in opioid and other analgesic medication requirements, which may contribute to decreased nausea, vomiting, and higher overall patient satisfaction with pain control.

Timeline

Start
2019-09-03
Primary completion
2021-07-23
Completion
2021-07-23

Outcome

Outcome not reported

Stopped (Business): “Insufficient funding to continue with study activities”

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Bupivacaine Other / unclassified 0.25 % Other
Subject Bupivacaine Other / unclassified 0.5 % Other
Subject Bupivacaine Other / unclassified — Other

Indications

No indication recorded.